Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics in a deal that brings brelovitug, a late‑stage monoclonal antibody for chronic hepatitis D (HDV), into Mirum’s rare liver disease pipeline. The transaction structure includes upfront cash and stock plus potential milestones tied to development and sales, and Mirum expects top‑line AZURE Phase III data in 2H 2026 with potential regulatory filings in 2027. Brelovitug showed strong antiviral activity in Phase II, with complete HDV RNA responses and favorable liver enzyme changes, the Bluejay team reported. Mirum framed the acquisition as complementary to its existing rare liver programs (volixibat and LIVMARLI) and said the asset leverages its commercial and regulatory expertise in hepatology. The deal highlights biopharma interest in consolidating rare‑disease assets where streamlined registrational paths and breakthrough/PRIME designations can accelerate timelines. For investors, Mirum’s bet compresses clinical milestones into a near‑term value inflection profile tied to the AZURE readout.